Moderna (NASDAQ:MRNA) Earns “Market Perform” Rating from William Blair

William Blair restated their market perform rating on shares of Moderna (NASDAQ:MRNA) in a report issued on Thursday morning, RTT News reports.

Other analysts have also issued research reports about the stock. Royal Bank of Canada increased their price target on shares of Moderna from $135.00 to $160.00 and gave the stock an outperform rating in a research report on Monday, June 3rd. UBS Group increased their price target on shares of Moderna from $143.00 to $151.00 and gave the stock a buy rating in a research report on Tuesday, May 7th. Evercore ISI reissued an in-line rating and issued a $120.00 price objective on shares of Moderna in a research note on Thursday. Oppenheimer increased their price objective on shares of Moderna from $163.00 to $179.00 and gave the company an outperform rating in a research note on Wednesday, June 12th. Finally, Canaccord Genuity Group increased their price objective on shares of Moderna from $91.00 to $106.00 and gave the company a hold rating in a research note on Friday, May 3rd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of Hold and an average price target of $134.02.

Moderna Stock Down 2.0 %

Shares of MRNA stock opened at $118.75 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. The firm’s 50-day moving average is $134.13 and its 200-day moving average is $112.19. The stock has a market cap of $45.51 billion, a price-to-earnings ratio of -7.58 and a beta of 1.54. Moderna has a 52-week low of $62.55 and a 52-week high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. During the same quarter in the prior year, the business earned $0.19 EPS. Moderna’s quarterly revenue was down 91.0% on a year-over-year basis. Sell-side analysts predict that Moderna will post -7.46 EPS for the current year.

Insider Buying and Selling at Moderna

In other Moderna news, CFO James M. Mock sold 705 shares of the stock in a transaction on Monday, April 8th. The shares were sold at an average price of $101.93, for a total transaction of $71,860.65. Following the completion of the sale, the chief financial officer now owns 5,048 shares of the company’s stock, valued at approximately $514,542.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CFO James M. Mock sold 705 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $101.93, for a total value of $71,860.65. Following the completion of the sale, the chief financial officer now directly owns 5,048 shares of the company’s stock, valued at approximately $514,542.64. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO James M. Mock sold 648 shares of Moderna stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total transaction of $105,280.56. Following the transaction, the chief financial officer now directly owns 5,726 shares of the company’s stock, valued at $930,303.22. The disclosure for this sale can be found here. Insiders sold 411,255 shares of company stock valued at $56,118,931 in the last quarter. Company insiders own 15.70% of the company’s stock.

Institutional Trading of Moderna

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Quadrant Capital Group LLC grew its stake in shares of Moderna by 7.5% in the fourth quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock worth $266,000 after acquiring an additional 187 shares during the period. International Assets Investment Management LLC grew its position in Moderna by 6,528.9% during the fourth quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock valued at $38,552,000 after buying an additional 381,808 shares during the period. abrdn plc grew its position in Moderna by 477.5% during the fourth quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after buying an additional 399,843 shares during the period. Ontario Teachers Pension Plan Board bought a new stake in Moderna during the fourth quarter valued at approximately $1,358,000. Finally, Hobbs Group Advisors LLC bought a new stake in Moderna during the fourth quarter valued at approximately $664,000. 75.33% of the stock is currently owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.